片仔癀再做LP，这次投了中金资本

Core Viewpoint - Pizhou Pharmaceutical has made a strategic investment in the healthcare sector by becoming a limited partner in the newly established CICC Medical Fund, contributing 200 million RMB, which represents 20% of the fund's target size of 1 billion RMB [1][2][3] Group 1: Investment Details - The CICC Medical Fund was established on October 14, with a target fundraising size of 1 billion RMB, and Pizhou Pharmaceutical's subsidiary, Zhangzhou Pizhou Investment Management Co., Ltd., is a limited partner contributing 200 million RMB [1][2] - The fund's primary investment focus includes traditional Chinese medicine, biomedicine, medical devices, healthcare services, and beauty and wellness industries, aligning with Pizhou's strategic interests [2][3] Group 2: Strategic Implications - Pizhou Pharmaceutical views this investment as a forward-looking strategy to enhance its core competitiveness while ensuring stable development of its main business [3] - The collaboration with CICC Capital is expected to leverage their extensive fund management experience and resources to integrate industry and capital effectively, supporting the long-term development of Pizhou and the healthcare industry in Zhangzhou [3] Group 3: Previous Investments - This is not Pizhou's first foray into the limited partner space; earlier in 2023, the company invested in two other funds, each with a similar contribution of 200 million RMB, focusing on the healthcare supply chain and biomedicine [4][5] - The previous investments are aimed at diversifying risks and linking innovative resources, which may provide future material supply guarantees for Pizhou's core products [5]